SPINK1 and cancer: Although PSC27-BLEO CM increased the viability of PC3 exposed to MIT at 0.1–1.0 μM, a range of dose close to its serum concentrations in cancer patients, SPINK1-neutralization offset cancer resistance in a similar way as SPINK1 mAb was co-applied with cetuximab (P < 0.01) (Fig. 4h; Supplementary Fig. 4l).